Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|Gastrinoma|Glucagonoma|HER2-negative Breast Cancer|Insulinoma|Mucositis|Oral Complications|Pancreatic Polypeptide Tumor|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Recurrent Islet Cell Carcinoma|Recurrent Renal Cell Cancer|Somatostatinoma|Stage III Renal Cell Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Renal Cell Cancer
Interventions: DRUG: Everolimus
Sponsor: Emory University
Collaborators: Novartis